Home Featured Page 114

Featured

Latest

Psilocybin for OCD: Terence Ching on Lessons from Yale’s Randomised Trials

Pα+ Psychedelic Bulletin #220: New State Bills; Congressional Mentions; Published Psilocybin, DMT, and Methylone Studies; RAND Polling Reveals 23% of Americans Support Legal Psilocybin...

Seeing Through the Veil: Why Psychedelic Experiences Often Feel More Real Than Ordinary Life

COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results ...

Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones...

Looking Ahead to a Psychedelic 2023

PT393 – Religious Freedom and the Church of Psilomethoxin

COMPASS Pathways plc to announce fourth quarter and year-end 2022 financial...

Opinions | Do Mice Hallucinate? Do Humans Head-Twitch?

Numinus to Participate in a Water Tower Research Fireside Chat on...

MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

PT392 – Vital Psychedelic Conversations

Psilocybin for OCD: Terence Ching on Lessons from Yale’s Randomised Trials

Pα+ Psychedelic Bulletin #220: New State Bills; Congressional Mentions; Published Psilocybin,...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psilocybin for OCD: Terence Ching on Lessons from Yale’s Randomised Trials

Pα+ Psychedelic Bulletin #220: New State Bills; Congressional Mentions; Published Psilocybin, DMT, and Methylone Studies; RAND Polling Reveals 23% of Americans Support Legal Psilocybin...

Pα+ Psychedelic Bulletin #220: New State Bills; Congressional Mentions; Published Psilocybin, DMT, and Methylone Studies; RAND Polling Reveals 23% of Americans Support Legal Psilocybin...

Seeing Through the Veil: Why Psychedelic Experiences Often Feel More Real Than Ordinary Life

Seeing Through the Veil: Why Psychedelic Experiences Often Feel More Real Than Ordinary Life

COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results ...

Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones...

Looking Ahead to a Psychedelic 2023

PT393 – Religious Freedom and the Church of Psilomethoxin

COMPASS Pathways plc to announce fourth quarter and year-end 2022 financial...

Opinions | Do Mice Hallucinate? Do Humans Head-Twitch?

Numinus to Participate in a Water Tower Research Fireside Chat on...

MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

PT392 – Vital Psychedelic Conversations

Panel: Psychedelic Careers

EDITOR PICKS

Psilocybin for OCD: Terence Ching on Lessons from Yale’s Randomised Trials

Pα+ Psychedelic Bulletin #220: New State Bills; Congressional Mentions; Published Psilocybin,...

Pα+ Psychedelic Bulletin #220: New State Bills; Congressional Mentions; Published Psilocybin,...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY